News
SGEN
228.74
+0.30%
0.65
UPDATE 1-Pfizer's drug succeeds in late-stage blood cancer trial
Pfizer's drug Adcetris succeeds in late-stage blood cancer trial. Drug met main goal of extending survival in patients with a type of blood cancer. The drug is already approved to treat other types of lymphomas. Pfizer gained the drug through its purchase of Seagen last year.
Reuters · 03/12 11:11
BUZZ-LAVA Therapeutics rises after getting milestone payment from Pfizer
Shares of drug developer LAVA Therapeutics rise 10.2% to $3.34 premarket. Company says it has received a milestone payment of $7 million from Pfizer. Company's experimental cancer drug PF-08046052 entered into early-stage trials.
Reuters · 03/05 13:29
Weekly Report: what happened at SGEN last week (0226-0301)?
Weekly Report · 03/04 09:12
Weekly Report: what happened at SGEN last week (0219-0223)?
Weekly Report · 02/26 09:13
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer completed its acquisition of Seagen Inc, a biotechnology leader in transformative cancer medicines. Moderna Inc is also betting its growth story on revolutionizing cancer treatment. Mainz Biomed N.V. Is making breakthroughs in early diagnostics. Early screening and better prevention are key to changing the odds in the battle against cancer.
Benzinga · 02/22 17:21
Weekly Report: what happened at SGEN last week (0212-0216)?
Weekly Report · 02/19 09:14
Weekly Report: what happened at SGEN last week (0205-0209)?
Weekly Report · 02/12 09:13
Weekly Report: what happened at SGEN last week (0129-0202)?
Weekly Report · 02/05 09:14
UPDATE 1-Pfizer posts surprise quarterly profit on resilient COVID products demand
Pfizer posts surprise quarterly profit on resilient COVID products demand. Shares of the U.S. Drugmaker rose 1.9% in premarket trading. Investors fled Pfizer last year as billions of dollars in COVID vaccine and treatment sales disappeared. The company is targeting a return to profitability.
Reuters · 01/30 11:57
Pfizer Q4 results on deck amid gloomy earnings outlook
Seeking Alpha · 01/29 17:15
Weekly Report: what happened at SGEN last week (0122-0126)?
Weekly Report · 01/29 09:13
Weekly Report: what happened at SGEN last week (0115-0119)?
Weekly Report · 01/22 09:13
Pfizer faces setback in Enhertu patent dispute with Daiichi
Healthcare Pfizer faces setback in Enhertu patent dispute with Daiichi. U.S. Patent and Trademark Office has invalidated all claims made by Pfizer’s recent buyout, Seagen, regarding a patent related to cancer therapy. The dispute involves a cancer therapy marketed by Daiichi Sankyo and AstraZeneca.
Seeking Alpha · 01/17 12:08
Weekly Report: what happened at SGEN last week (0108-0112)?
Weekly Report · 01/15 09:13
Pfizer to remain aggressive on obesity market after setback
Pfizer to remain aggressive on obesity market after setback. Company dropped a high profile weight-loss drug candidate late last year due to strong side effects. Pfizer has been punished by investors for a string of disappointing results. Analysts say obesity drug market could reach $100 billion by end of the decade.
Reuters · 01/08 23:00
Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B
Johnson & Johnson to acquire ADC developer Ambrx Biopharma for $2B. The deal will add several cancer drug candidates to the pharma giant's pipeline. The companies announced the acquisition of a new class of cancer drugs called antibody-drug conjugates. JNJ shares climbed 29% premarket in reaction to the news. The transaction is expected to close in 2024.
Seeking Alpha · 01/08 12:52
Weekly Report: what happened at SGEN last week (0101-0105)?
Weekly Report · 01/08 09:13
J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, AI pick up
Healthcare J.P. Morgan event in spotlight as biotech M&A, obesity frenzy, and AI pick up. The four-day event is set to kick off on Monday in San Francisco, CA. The recent momentum in biotech deal-making, the rising interest in weight-loss drugs, and the popularity of artificial intelligence will be key themes.
Seeking Alpha · 01/07 17:00
Pfizer: Paying Too Much To Boost Revenues
Pfizer needs new revenue streams in a post-COVID world with patent cliffs on the horizon. Pfizer has generally paid high prices for M&A, above industry norms. Oncology has been a lagging business for Pfizer despite being a hot growth area. The company is marching towards a patent cliff.
Seeking Alpha · 01/06 10:10
Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
Madrigal Pharmaceuticals, Inc. Stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. The NASH market is estimated to reach $20 billion by 2030.
Seeking Alpha · 01/02 16:12
More
Webull provides a variety of real-time SGEN stock news. You can receive the latest news about Seagen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SGEN
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.